<DOC>
	<DOCNO>NCT00781170</DOCNO>
	<brief_summary>To evaluate feasibility efficacy autologous stem cell transplantation follow Melphalan/ Fludarabine base dose-reduced allograft HLA-identical HLA-compatible unrelated donor patient Multiple Myeloma . In non complete remission DLI and/ new agent Bortezomib , Thalidomid Lenalidomide use upgrade remission .</brief_summary>
	<brief_title>Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Multiple Myeloma Stadium II / III acc . Salmon Durie sign informed consent adequate organ function prior autologous respectively allogeneic SCT availability HLAidentical relate unrelated donor availability least 2 x 10^6 CD34+ cell per kg BW recipient autologous SCT least 3 x 10^6 CD34+ cell allogeneic SCT MRDSCT : 1866 year ; MUDSCT : 1855 year age &lt; 55 year existence risk factor make myeloablative allogeneic transplantation risky consent donor give DLI severe heart insufficiency cardiovascular disease severe concomitant disease active infection need antibiotic therapy positive HIV hepatitis malign secondary disease limit liver function total bilirubin &gt; 1.5 ULN increase transaminase &gt; 3 ULN increase serum creatinine &gt; 2 mg/dl pregnant lactating woman know hypersensitivity Fludarabine Melphalan participation another trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Plasmocytoma</keyword>
	<keyword>Stem Cell Transplantation</keyword>
</DOC>